The versatile MHC class I-related FcRn protects IgG and albumin from degradation: Implications for development of new diagnostics and therapeutics

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 4, 2009, Pages 318-332

  Andersen, Jan Terje ^a   Sandlie, Inger ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Albumin; Albumin targeting; Genetic fusion; Half life; IgG; Neonatal Fc receptor (FcRn); pH dependent; Recycling

Indexed keywords

ALBUMIN; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE;

ALBUMIN BLOOD LEVEL; ANTIGEN BINDING; CONFERENCE PAPER; CRYSTAL STRUCTURE; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY CARCINOMA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS;

EID: 70350438004     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.318     Document Type: Conference Paper

References (160)

1. Peters, T. J.: All about Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, Academic Press, 1996.
2. Kragh-Hansen, U., Chuang, V. T. and Otagiri, M.: Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull., 25: 695-704 (2002).
3. He, X. M. and Carter, D. C.: Atomic structure and chemistry of human serum albumin. Nature, 358: 209-215 (1992).
4. Carter, D. C., He, X. M., Munson, S. H., Twigg, P. D., Gernert, K. M., Broom, M. B. and Miller, T. Y.: Three-dimensional structure of human serum albumin. Science, 244: 1195-1198 (1989).
5. Curry, S., Brick, P. and Franks, N. P.: Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim. Biophys. Acta., 1441:, 131-140 (1999).
6. Bhattacharya, A. A., Grune, T. and Curry, S.: Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol., 303:, 721-732 (2000).
7. Waldmann, T. A. and Strober, W.: Metabolism of immunoglobulins. Prog. Allergy., 13: 1-110 (1969).
8. Spiegelberg, H. L. and Fishkin, B. G.: The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins. Clin. Exp. Immunol., 10: 599-607 (1972).
9. Peters, T., Jr.: Serum albumin. Adv. Protein. Chem., 37: 161-245 (1985).
10. Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C. and Anderson, C. L.: The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med., 197: 315-322 (2003).
11. Ghetie, V. and Ward, E. S.: Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol., 18: 739-766 (2000).
12. Brambell, F. W.: The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet, 2: 1087-1093 (1966).
13. Brambell, F. W., Hemmings, W. A., Oakley, C. L. and Porter, R. R.: The relative transmission of the fractions of papain hydrolyzed homologous gamma-globulin from the uterine cavity to the foetal circulation in the rabbit. Proc. R. Soc. Lond. B. Biol. Sci., 151: 478-482 (1960).
14. Halliday, R.: Prenatal and postnatal transmission of passive immunity to young rats. Proc. R. Soc. Lond. B. Biol. Sci., 144: 427-430 (1955).
15. Halliday, R.: The absorption of antibodies from immune sera by the gut of the young rat. Proc. R. Soc. Lond. B. Biol. Sci., 143: 408-413 (1955).
16. Bamford, D. R.: Studies in vitro of the passage of serum proteins across the intestinal wall of young rats. Proc. R. Soc. Lond. B. Biol. Sci., 166: 30-45 (1966).
17. Fahey, J. L. and Robinson, A. G.: Factors Controlling Serum Gamma-Globulin Concentration. J. Exp. Med., 118: 845-868 (1963).
18. Brambell, F. W., Hemmings, W. A. and Morris, I. G.: A Theoretical Model Of Gamma-Globulin Catabolism. Nature, 203: 1352-1354 (1964).
19. Simister, N. E. and Mostov, K. E.: An Fc receptor structurally related to MHC class I antigens. Nature, 337: 184-187 (1989).
20. Junghans, R. P. and Anderson, C. L.: The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA, 93: 5512-5516 (1996).
21. Martin, M. G., Wu, S. V. and Walsh, J. H.: Ontogenetic development and distribution of antibody transport and Fc receptor mRNA expression in rat intestine. Dig Dis. Sci., 42: 1062-1069 (1997).
22. McCarthy, K. M., Yoong, Y. and Simister, N. E.: Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J. Cell Sci., 113 (Pt 7): 1277-1285 (2000).
23. Haymann, J. P., Levraud, J. P., Bouet, S., Kappes, V., Hagege, J., Nguyen, G., Xu, Y., Rondeau, E. and Sraer, J.D.: Characterization and localization of the neonatal Fc receptor in adult human kidney. J. Am. Soc. Nephrol, 11: 632-639 (2000).
24. Akilesh, S., Huber, T. B., Wu, H., Wang, G., Hartleben, B., Kopp, J. B., Miner, J. H., Roopenian, D. C., Unanue, E. R. and Shaw, A. S.: Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl. Acad. Sci. USA, 105: 967-972 (2008).
25. Blumberg, R. S., Koss, T., Story, C. M., Barisani, D., Polischuk, J., Lipin, A., Pablo, L., Green, R. and Simister, N. E.: A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J. Clin. Invest., 95: 2397-2402 (1995).
26. Akilesh, S., Christianson, G. J., Roopenian, D. C. and Shaw, A. S.: Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol., 179: 4580-4588 (2007).
27. Telleman, P. and Junghans, R. P.: The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology, 100: 245-251 (2000).
28. Story, C. M., Mikulska, J. E. and Simister, N. E.: A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med., 180: 2377-2381 (1994).
29. Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V. and Ward, E. S.: The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int. Immunol., 13: 993-1002 (2001).
30. Schultze, H. E. and Heremans, J. F.: Molecular biology of human proteins: with special reference to plasma proteins. Nature and Metabolism of Extracellular Proteins. 1: 904 (1966).
31. Gastinel, L. N., Simister, N. E. and Bjorkman, P. J.: Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc. Natl. Acad. Sci. USA, 89: 638-642 (1992).
32. West, A. P., Jr. and Bjorkman, P. J.: Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry, 39: 9698-9708 (2000).
33. Burmeister, W. P., Huber, A. H. and Bjorkman, P. J.: Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 372: 379-383 (1994).
34. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L. and Bjorkman, P. J.: Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature, 372: 336-343 (1994).
35. Kim, J. K., Firan, M., Radu, C. G., Kim, C. H., Ghetie, V. and Ward, E. S.: Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol., 29: 2819-2825 (1999).
36. Medesan, C., Matesoi, D., Radu, C., Ghetie, V. and Ward, E. S.: Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol., 158: 2211-2217 (1997).
37. Popov, S., Hubbard, J. G., Kim, J., Ober, B., Ghetie, V. and Ward, E. S.: The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol. Immunol., 33: 521-530 (1996).
38. Raghavan, M., Bonagura, V. R., Morrison, S. L. and Bjorkman, P. J.: Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry, 34: 14649-14657 (1995).
39. Raghavan, M., Chen, M. Y., Gastinel, L. N. and Bjorkman, P. J.: Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity, 1: 303-315 (1994).
40. Raghavan, M., Gastinel, L. N. and Bjorkman, P. J.: The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry, 32: 8654-8660 (1993).
41. Vaughn, D. E. and Bjorkman, P. J.: Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure, 6: 63-73 (1998).
42. Vaughn, D. E., Milburn, C. M., Penny, D. M., Martin, W. L., Johnson, J. L. and Bjorkman, P. J.: Identification of critical IgG binding epitopes on the neonatal Fc receptor. J. Mol. Biol., 274: 597-607 (1997).
43. Andersen, J. T., Dee Qian, J. and Sandlie, I.: The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur. J. Immunol., 36: 3044-3051 (2006).
44. Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M. and Anderson, C. L.: Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry, 45: 4983-4990 (2006).
45. Andersen, J. T., Justesen, S., Fleckenstein, B., Michaelsen, T. E., Berntzen, G., Kenanova, V. E., Daba, M. B., Lauvrak, V., Buus, S. and Sandlie, I.: Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. Febs J., 275: 4097-4110 (2008).
46. Wani, M. A., Haynes, L. D., Kim, J., Bronson, C. L., Chaudhury, C., Mohanty, S., Waldmann, T. A., Robinson, J. M. and Anderson, C. L.: Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc. Natl. Acad. Sci. USA, 103: 5084-5089 (2006).
47. Vidarsson, G., Stemerding, A. M., Stapleton, N. M., Spliethoff, S. E., Janssen, H., Rebers, F. E., de Haas, M. and van de Winkel, J. G.: FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood, 108: 3573-3579 (2006).
48. Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S. and Lencer, W. I.: Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest., 104: 903-911 (1999).
49. Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J. and Ward, E. S.: Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J. Immunol., 172: 2021-2029 (2004).
50. Ober, R. J., Martinez, C., Lai, X., Zhou, J. andWard, E. S.: Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl. Acad. Sci. USA, 101: 11076-11081 (2004).
51. Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W. and Ward, E. S.: Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. USA, 106: 2788-2793 (2009).
52. Qiao, S. W., Kobayashi, K., Johansen, F. E., Sollid, L. M., Andersen, J. T., Milford, E., Roopenian, D. C., Lencer, W.I. and Blumberg, R. S.: Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. USA, 105: 9337-9342 (2008).
53. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S., Avanessian, L., Choi, E. Y., Shaffer, D. J., Eden, P. A. and Anderson, C. L.: The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol., 170: 3528-3533 (2003).
54. Yoshida, M., Claypool, S. M., Wagner, J. S., Mizoguchi, E., Mizoguchi, A., Roopenian, D. C., Lencer, W. I. and Blumberg, R. S.: Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity, 20: 769-783 (2004).
55. Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S. and Lencer, W. I.: Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med., 196: 303-310 (2002).
56. Yoshida, M., Kobayashi, K., Kuo, T. T., Bry, L., Glickman, J. N., Claypool, S. M., Kaser, A., Nagaishi, T., Higgins, D. E., Mizoguchi, E., Wakatsuki, Y., Roopenian, D. C., Mizoguchi, A., Lencer, W. I. and Blumberg, R. S.: Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J. Clin. Invest., 116: 2142-2151 (2006).
57. Dumont, J. A., Bitonti, A. J., Clark, D., Evans, S., Pickford, M. and Newman, S. P.: Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol. Med., 18: 294-303 (2005).
58. Bitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., Garcia, A. M., Simister, N. E., Spiekermann, G. M., Lencer, W. I. and Blumberg, R. S.: Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA, 101: 9763-9768 (2004).
59. Medesan, C., Radu, C., Kim, J. K., Ghetie, V. and Ward, E. S.: Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur. J. Immunol., 26: 2533-2536 (1996).
60. Grubb, J. H., Vogler, C., Tan, Y., Shah, G. N., MacRae, A. F. and Sly, W. S.: Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc. Natl. Acad. Sci. USA, 105: 8375-8380 (2008).
61. Kim, J., Bronson, C. L., Hayton, W. L., Radmacher, M. D., Roopenian, D. C., Robinson, J. M. and Anderson, C. L.: Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. Gastrointest Liver Physiol., 290: G352-360 (2006).
62. Kenanova, V., Olafsen, T., Williams, L. E., Ruel, N. H., Longmate, J., Yazaki, P. J., Shively, J. E., Colcher, D., Raubitschek, A. A. and Wu, A. M.: Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res., 67: 718-726 (2007).
63. Prinsen, B. H., Rabelink, T. J., Beutler, J. J., Kaysen, G. A., De Boer, J., Boer,W. H., Hagen, E. C., Berger, R. and De Sain-Van Der Velden, M. G.: Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int., 64: 1495-1504 (2003).
64. Kim, J., Hayton, W. L., Robinson, J. M. and Anderson, C. L.: Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin. Immunol., 122: 146-155 (2007).
65. Ober, R. J., Radu, C. G., Ghetie, V. and Ward, E. S.: Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol., 13: 1551-1559 (2001).
66. Andersen, J. T., Justesen, S., Berntzen, G., Michaelsen, T. E., Lauvrak, V., Fleckenstein, B., Buus, S. and Sandlie, I.: A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J. Immunol. Methods, 331: 39-49 (2008).
67. Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G. and Roopenian, D. C.: Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol., 18: 1759-1769 (2006).
68. Minchiotti, L., Galliano, M., Kragh-Hansen, U. and Peters, T., Jr.: Mutations and polymorphisms of the gene of the major human blood protein, serum albumin. Hum. Mutat., 29: 1007-1016 (2008).
69. Andersen, J. T. and Sandlie, I.: A Receptor-Mediated Mechanism to Support Clinical Observation of Altered Albumin Variants. Clinical Chemistry, 53: 2216 (2007).
70. Almogren, A., Furtado, P. B., Sun, Z., Perkins, S. J. and Kerr, M. A.: Purification, properties and extended solution structure of the complex formed between human immunoglobulin A1 and human serum albumin by scattering and ultracentrifugation. J. Mol. Biol., 356: 413-431 (2006).
71. Vaerman, J. P., Hagiwara, K., Kobayashi, K. and Rits, M.: Complexes of albumin and alpha 1-antitrypsin with Fc-fragment of IgA monomer are disulfide-bound to penultimate C-terminal cysteine in the C alpha 3-domain. Immunol. Lett., 15: 67-72 (1987).
72. Mestecky, J., Hammack, W. J., Kulhavy, R., Wright, G. P. and Tomana, M.: Properties of IgA myeloma proteins isolated rom sera of patients with the hyperviscosity syndrome. J. Lab. Clin. Med., 89: 919-927 (1977).
73. Schlachetzki, F., Zhu, C. and Pardridge, W. M.: Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem, 81: 203-206 (2002).
74. Ballabh, P., Braun, A. and Nedergaard, M.: The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis., 16: 1-13 (2004).
75. Zhang, Y. and Pardridge, W. M.: Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J. Neuroimmunol, 114: 168-172 (2001).
76. Deane, R., Sagare, A., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M. and Zlokovic, B. V.: IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci., 25: 11495-11503 (2005).
77. Werle, M. and Bernkop-Schnurch, A.: Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 30: 351-367 (2006).
78. McGregor, D. P.: Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol., 8: 616-619 (2008).
79. Kohler, G. and Milstein, C.: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256: 495-497 (1975).
80. Hoogenboom, H. R.: Selecting and screening recombinant antibody libraries. Nat. Biotechnol., 23: 1105-1116 (2005).
81. Brekke, O. H. and Sandlie, I.: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov., 2: 52-62 (2003).
82. Wu, A. M. and Senter, P. D.: Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 23: 1137-1146 (2005).
83. Reichert, J. M.: Monoclonal antibodies in the clinic. Nat. Biotechnol., 19: 819-822 (2001).
84. Boulianne, G. L., Hozumi, N. and Shulman, M. J.: Production of functional chimaeric mouse/human antibody. Nature, 312: 643-646 (1984).
85. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. and Winter, G.: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 321: 522-525 (1986).
86. Zhou, J., Mateos, F., Ober, R. J. and Ward, E. S.: Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J. Mol. Biol., 345: 1071-1081 (2005).
87. Jazayeri, J. A. and Carroll, G. J.: Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs, 22: 11-26 (2008).
88. Dumont, J. A., Low, S. C., Peters, R. T. and Bitonti, A. J.: Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs, 20: 151-160 (2006).
89. Cines, D. B., Yasothan, U. and Kirkpatrick, P.: Romiplostim. Nat. Rev. Drug Discov., 7: 887-888 (2008).
90. Goldenberg, M. M.: Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther., 21: 75-87; discussion 71-72 (1999).
91. Vaccaro, C., Zhou, J., Ober, R. J. and Ward, E. S.: Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol., 23: 1283-1288 (2005).
92. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. and Ward, E. S.: Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl. Acad. Sci. USA, 103: 18709-18714 (2006).
93. Mi, W., Wanjie, S., Lo, S. T., Gan, Z., Pickl-Herk, B., Ober, R. J. and Ward, E. S.: Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. J. Immunol., 181: 7550-7561 (2008).
94. Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S. and Tsurushita, N.: An engineered human IgG1 antibody with longer serum half-life. J. Immunol., 176: 346-356 (2006).
95. Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vasquez, M. and Tsurushita, N.: Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem., 279: 6213-6216 (2004).
96. Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J. and Ward, E. S.: Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol., 15: 637-640 (1997).
97. Dall'Acqua, W. F., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A.,Wu, H., Kiener, P. A. and Langermann, S.: Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol., 169: 5171-5180 (2002).
98. Dall'Acqua, W. F., Kiener, P. A. and Wu, H.: Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem., 281: 23514-23524 (2006).
99. Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J., Jiang, W. and Wroblewski, V. J.: Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos., 35: 86-94 (2007).
100. Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. and Wroblewski, V. J.: Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J. Biol. Chem., 282: 1709-1717 (2007).
101. Nimmerjahn, F. and Ravetch, J. V.: Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol., 26: 513-533 (2008).
102. Masson, P. L.: Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J. Autoimmun., 6: 683-689 (1993).
103. Li, N., Zhao, M., Hilario-Vargas, J., Prisayanh, P., Warren, S., Diaz, L. A., Roopenian, D. C. and Liu, Z.: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest., 115: 3440-3450 (2005).
104. Akilesh, S., Petkova, S., Sproule, T. J., Shaffer, D. J., Christianson, G. J. and Roopenian, D.: The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest., 113: 1328-1333 (2004).
105. Jaggi, J. S., Carrasquillo, J. A., Seshan, S. V., Zanzonico, P., Henke, E., Nagel, A., Schwartz, J., Beattie, B., Kappel, B. J., Chattopadhyay, D., Xiao, J., Sgouros, G., Larson, S. M. and Scheinberg, D. A.: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J. Clin. Invest., 117: 2422-2430 (2007).
106. Samuelsson, A., Towers, T. L. and Ravetch, J. V.: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science, 291: 484-486 (2001).
107. Anthony, R. M., Wermeling, F., Karlsson, M. C. and Ravetch, J. V.: Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA, 105: 19571-19578 (2008).
108. Liu, L., Garcia, A. M., Santoro, H., Zhang, Y., McDonnell, K., Dumont, J. and Bitonti, A.: Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J. Immunol., 178: 5390-5398 (2007).
109. Getman, K. E. and Balthasar, J. P.: Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J. Pharm. Sci., 94: 718-729 (2005).
110. Mezo, A. R., McDonnell, K. A., Hehir, C. A., Low, S. C., Palombella, V. J., Stattel, J. M., Kamphaus, G. D., Fraley, C., Zhang, Y., Dumont, J. A. and Bitonti, A. J.: Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc. Natl. Acad. Sci. USA, 105: 2337-2342 (2008).
111. Marino, M., Ruvo, M., De Falco, S. and Fassina, G.: Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol., 18: 735-739 (2000).
112. DeLano, W. L., Ultsch, M. H., de Vos, A. M. and Wells, J. A.: Convergent solutions to binding at a protein-protein interface. Science, 287: 1279-1283 (2000).
113. Olafsen, T., Kenanova, V. E., Sundaresan, G., Anderson, A. L., Crow, D., Yazaki, P. J., Li, L., Press, M. F., Gambhir, S. S., Williams, L. E., Wong, J. Y., Raubitschek, A. A., Shively, J. E. and Wu, A. M.: Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res., 65: 5907-5916 (2005).
114. Kenanova, V. and Wu, A. M.: Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv., 3: 53-70 (2006).
115. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C., Hartung, G., Maier-Borst, W. and Heene, D. L.: Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol., 26: 77-100 (1997).
116. Kratz, F., Abu Ajaj, K. and Warnecke, A.: Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs, 16: 1037-1058 (2007).
117. Vis, A. N., van der Gaast, A., van Rhijn, B. W., Catsburg, T. K., Schmidt, C. and Mickisch, G. H.: A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother. Pharmacol., 49: 342-345 (2002).
118. Wunder, A., Muller-Ladner, U., Stelzer, E. H., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S. and Fiehn, C.: Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol., 170: 4793-4801 (2003).
119. Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L. and Heise, T.: Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab., 9: 290-299 (2007).
120. Koehler, M. F., Zobel, K., Beresini, M. H., Caris, L. D., Combs, D., Paasch, B. D. and Lazarus, R. A.: Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett., 12: 2883-2886 (2002).
121. Zobel, K., Koehler, M. F., Beresini, M. H., Caris, L. D. and Combs, D.: Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg. Med. Chem. Lett., 13: 1513-1515 (2003).
122. Home, P. and Kurtzhals, P.: Insulin detemir: from concept to clinical experience. Expert Opin. Pharmacother, 7: 325-343 (2006).
123. Giannoukakis, N.: CJC-1131. ConjuChem. Curr. Opin. Investig. Drugs., 4: 1245-1249 (2003).
124. Gradishar, W. J.: Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother., 7: 1041-1053 (2006).
125. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M. and O'Shaughnessy, J.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 23: 7794-7803 (2005).
126. Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L. and Palmieri, F. M.: Phase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann. Oncol., 20: 449-453 (2009).
127. Yeh, P., Landais, D., Lemaitre, M., Maury, I., Crenne, J. Y., Becquart, J., Murry-Brelier, A., Boucher, F., Montay, G., Fleer, R. et al.: Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin- CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA, 89: 1904-1908 (1992).
128. Syed, S., Schuyler, P. D., Kulczycky, M. and Sheffield, W. P.: Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin., 89: 3243-3252 (1997).
129. Duttaroy, A., Kanakaraj, P., Osborn, B. L., Schneider, H., Pickeral, O. K., Chen, C., Zhang, G., Kaithamana, S., Singh, M., Schulingkamp, R., Crossan, D., Bock, J., Kaufman, T. E., Reavey, P., Carey-Barber, M., Krishnan, S. R., Garcia, A., Murphy, K., Siskind, J. K., McLean, M. A., Cheng, S., Ruben, S., Birse, C. E., and Blondel, O.: Development of a long-acting insulin analog using albumin fusion technology. Diabetes, 54: 251-258 (2005).
130. Halpern, W., Riccobene, T. A., Agostini, H., Baker, K., Stolow, D., Gu, M. L., Hirsch, J., Mahoney, A., Carrell, J., Boyd, E. and Grzegorzewski, K. J.: Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res., 19: 1720-1729 (2002).
131. Osborn, B. L., Sekut, L., Corcoran, M., Poortman, C., Sturm, B., Chen, G., Mather, D., Lin, H. L. and Parry, T. J.: Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol., 456: 149-158 (2002).
132. Bain, V. G., Kaita, K. D., Yoshida, E. M., Swain, M. G., Heathcote, E. J., Neumann, A. U., Fiscella, M., Yu, R., Osborn, B. L., Cronin, P.W., Freimuth, W.W., McHutchison, J. G. and Subramanian, G. M.: A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol., 44: 671-678 (2006).
133. Subramanian, G. M., Fiscella, M., Lamouse-Smith, A., Zeuzem, S. and McHutchison, J. G.: Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol., 25: 1411-1419 (2007).
134. Sung, C., Nardelli, B., LaFleur, D. W., Blatter, E., Corcoran, M., Olsen, H. S., Birse, C. E., Pickeral, O. K., Zhang, J., Shah, D., Moody, G., Gentz, S., Beebe, L. and Moore, P. A.: An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Interferon Cytokine Res., 23: 25-36 (2003).
135. Glue, P., Fang, J. W., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S. K., Salfi, M. and Jacobs, S.: Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther., 68: 556-567 (2000).
136. Smith, B. J., Popplewell, A., Athwal, D., Chapman, A. P., Heywood, S., West, S. M., Carrington, B., Nesbitt, A., Lawson, A. D., Antoniw, P., Eddelston, A. and Suitters, A.: Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem., 12: 750-756 (2001).
137. Muller, D., Karle, A., Meissburger, B., Hofig, I., Stork, R. and Kontermann, R. E.: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem., 282: 12650-12660 (2007).
138. Muller, D. and Kontermann, R. E.: Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr. Opin. Mol. Ther., 9: 319-326 (2007).
139. Yazaki, P. J., Kassa, T., Cheung, C. W., Crow, D. M., Sherman, M. A., Bading, J. R., Anderson, A. L., Colcher, D. and Raubitschek, A.: Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl. Med. Biol., 35: 151-158 (2008).
140. Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D. and Tomlinson, I. M.: Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel., 21: 283-288 (2008).
141. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D. and Damico, L. A.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem., 277: 35035-35043 (2002).
142. Nguyen, A., Reyes, A. E., 2nd, Zhang, M., McDonald, P., Wong, W. L., Damico, L. A. and Dennis, M. S.: The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel., 19: 291-297 (2006).
143. Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S. and Schwall, R.: Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res., 67: 254-261 (2007).
144. Schlapschy, M., Theobald, I., Mack, H., Schottelius, M., Wester, H. J. and Skerra, A.: Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng. Des. Sel., 20: 273-284 (2007).
145. Makrides, S. C., Nygren, P. A., Andrews, B., Ford, P. J., Evans, K. S., Hayman, E. G., Adari,H., Uhlen, M. and Toth, C. A.: Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J. Pharmacol. Exp. Ther., 277: 534-542 (1996).
146. Nygren, P. A., Flodby, P., Andersson, R., Wigzell, H. and Uhlen, M.: In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum albumin-binding receptor. In Chanok, R. M. (ed.): Vaccines 91, Modern Approaches to Vaccine Development, New York, Cold Spring Harbor Laboratory Press, 1991, pp. 363-368.
147. Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandstrom, M., Rosik, D., Carlsson, J., Lundqvist, H., Wennborg, A. and Nilsson, F. Y.: Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res., 67: 2773-2782 (2007).
148. Nord, K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M. and Nygren, P. A.: Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol., 15: 772-777 (1997).
149. Stork, R., Muller, D. and Kontermann, R. E.: A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng. Des. Sel., 20: 569-576 (2007).
150. Linhult, M., Binz, H. K., Uhlen, M. and Hober, S.: Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci., 11: 206-213 (2002).
151. Iwao, Y., Anraku, M., Yamasaki, K., Kragh-Hansen, U., Kawai, K., Maruyama, T. and Otagiri, M.: Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim. Biophys. Acta., 1764: 743-749 (2006).
152. Iwao, Y., Hiraike, M., Kragh-Hansen, U., Kawai, K., Suenaga, A., Maruyama, T. and Otagiri, M.: Altered chain-length and glycosylation
153. Iwao, Y., Hiraike, M., Kragh-Hansen, U., Mera, K., Noguchi, T., Anraku, M., Kawai, K., Maruyama, T. and Otagiri, M.: Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin. Biochim. Biophys. Acta., 1774: 1582-1590 (2007).
154. Sheffield, W. P., Marques, J. A., Bhakta, V. and Smith, I. J.: Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. Thromb Res., 99: 613-621 (2000).
155. Nilsson, F.Y. and Tolmachev, V.: Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discov. Devel., 10: 167-175 (2007).
156. Stumpp, M. T. and Amstutz, P.: DARPins: a true alternative to antibodies. Curr. Opin. Drug Discov. Devel., 10: 153-159 (2007).
157. Revets, H., De Baetselier, P. and Muyldermans, S.: Nanobodies as novel agents for cancer therapy. Expert Opin. Biol. Ther., 5: 111-124 (2005).
158. Zhou, J., Pop, L. M. and Ghetie, V.: Hypercatabolism of IgG in mice with lupus-like syndrome. Lupus, 14: 458-466 (2005).
159. Sugio, S., Kashima, A., Mochizuki, S., Noda, M. and Kobayashi, K.: Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng., 12: 439-446 (1999).
160. Saphire, E. O., Parren, P. W., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R. and Wilson, I. A.: Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science, 293: 1155-1159 (2001).